HUP1600483A2 - - Google Patents

Info

Publication number
HUP1600483A2
HUP1600483A2 HUP1600483A HUP1600483A2 HU P1600483 A2 HUP1600483 A2 HU P1600483A2 HU P1600483 A HUP1600483 A HU P1600483A HU P1600483 A2 HUP1600483 A2 HU P1600483A2
Authority
HU
Hungary
Application number
Other languages
Hungarian (hu)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9893121&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP1600483(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of HUP1600483A2 publication Critical patent/HUP1600483A2/hu
Publication of HU230669B1 publication Critical patent/HU230669B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compression Of Band Width Or Redundancy In Fax (AREA)
HUP1600483A 2000-06-06 2001-06-05 Humán tumor nekrózis faktor alfa specifikus antitest molekulák és alkalmazásuk HU230669B1 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0013810.7A GB0013810D0 (en) 2000-06-06 2000-06-06 Biological products
PCT/GB2001/002477 WO2001094585A1 (en) 2000-06-06 2001-06-05 Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof

Publications (2)

Publication Number Publication Date
HUP1600483A2 true HUP1600483A2 (cg-RX-API-DMAC7.html) 2002-10-28
HU230669B1 HU230669B1 (hu) 2017-07-28

Family

ID=9893121

Family Applications (4)

Application Number Title Priority Date Filing Date
HU1600016A HU230553B1 (hu) 2000-06-06 2001-06-05 Humán tumor nekrózis faktor alfa specifikus antitest molekulák és alkalmazásuk
HU0202346A HU230561B1 (hu) 2000-06-06 2001-06-05 Humán tumor nekrózis faktor-alfa specifikus antitest molekulák és alkalmazásuk
HUP1600483A HU230669B1 (hu) 2000-06-06 2001-06-05 Humán tumor nekrózis faktor alfa specifikus antitest molekulák és alkalmazásuk
HUS1700013C HUS1700013I1 (hu) 2000-06-06 2017-04-06 Humán tumor nekrózis faktor-alfa specifikus antitest molekulák és alkalmazásuk

Family Applications Before (2)

Application Number Title Priority Date Filing Date
HU1600016A HU230553B1 (hu) 2000-06-06 2001-06-05 Humán tumor nekrózis faktor alfa specifikus antitest molekulák és alkalmazásuk
HU0202346A HU230561B1 (hu) 2000-06-06 2001-06-05 Humán tumor nekrózis faktor-alfa specifikus antitest molekulák és alkalmazásuk

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUS1700013C HUS1700013I1 (hu) 2000-06-06 2017-04-06 Humán tumor nekrózis faktor-alfa specifikus antitest molekulák és alkalmazásuk

Country Status (42)

Country Link
US (4) US7012135B2 (cg-RX-API-DMAC7.html)
EP (4) EP2230308B1 (cg-RX-API-DMAC7.html)
JP (3) JP4064812B2 (cg-RX-API-DMAC7.html)
KR (1) KR20020047097A (cg-RX-API-DMAC7.html)
CN (1) CN1289671C (cg-RX-API-DMAC7.html)
AP (1) AP2092A (cg-RX-API-DMAC7.html)
AR (1) AR033978A1 (cg-RX-API-DMAC7.html)
AT (1) ATE451460T1 (cg-RX-API-DMAC7.html)
AU (1) AU783756B2 (cg-RX-API-DMAC7.html)
BE (1) BE2010C019I2 (cg-RX-API-DMAC7.html)
BG (1) BG66072B1 (cg-RX-API-DMAC7.html)
BR (2) BR0106682A (cg-RX-API-DMAC7.html)
CA (2) CA2707766C (cg-RX-API-DMAC7.html)
CY (6) CY1109889T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ300737B6 (cg-RX-API-DMAC7.html)
DE (3) DE122010000027I1 (cg-RX-API-DMAC7.html)
DK (4) DK2308975T3 (cg-RX-API-DMAC7.html)
EC (1) ECSP024210A (cg-RX-API-DMAC7.html)
ES (5) ES2403217T3 (cg-RX-API-DMAC7.html)
FR (1) FR10C0015I2 (cg-RX-API-DMAC7.html)
GB (2) GB0013810D0 (cg-RX-API-DMAC7.html)
HU (4) HU230553B1 (cg-RX-API-DMAC7.html)
IL (3) IL147992A0 (cg-RX-API-DMAC7.html)
IS (2) IS2808B (cg-RX-API-DMAC7.html)
LT (1) LT2308975T (cg-RX-API-DMAC7.html)
LU (1) LU91674I2 (cg-RX-API-DMAC7.html)
MX (1) MXPA01013440A (cg-RX-API-DMAC7.html)
MY (1) MY136603A (cg-RX-API-DMAC7.html)
NL (1) NL300982I9 (cg-RX-API-DMAC7.html)
NO (4) NO334808B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ516596A (cg-RX-API-DMAC7.html)
OA (1) OA12282A (cg-RX-API-DMAC7.html)
PE (1) PE20020292A1 (cg-RX-API-DMAC7.html)
PL (2) PL218516B1 (cg-RX-API-DMAC7.html)
PT (4) PT3059314T (cg-RX-API-DMAC7.html)
RU (1) RU2303604C2 (cg-RX-API-DMAC7.html)
SI (3) SI1287140T1 (cg-RX-API-DMAC7.html)
SK (1) SK288343B6 (cg-RX-API-DMAC7.html)
TR (1) TR201900227T4 (cg-RX-API-DMAC7.html)
TW (2) TWI316088B (cg-RX-API-DMAC7.html)
WO (1) WO2001094585A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200200097B (cg-RX-API-DMAC7.html)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
GB0129105D0 (en) * 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
ES2358505T3 (es) * 2002-03-20 2011-05-11 Ucb Pharma, S.A. Métodos para analizar isómeros de disulfuro de anticuerpos.
US20040009172A1 (en) * 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
BR122019027974B1 (pt) 2002-05-02 2022-06-14 Wyeth Holdings Corporation Composição compreendendo conjugado monomérico de derivado de caliqueamicina/anticorpo anti-cd22 e seu uso
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
US7601817B2 (en) 2002-05-28 2009-10-13 Ucb Pharma S.A. Antibody peg positional isomers, compositions comprising same, and use thereof
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
CA2493067A1 (en) * 2002-07-19 2004-01-29 Abbott Biotechnology Ltd. Treatment of tnf.alpha. related disorders
AU2003276844A1 (en) * 2002-08-28 2004-03-19 Pharmacia Corporation Formulations of modified antibodies and methods of making the same
AU2003265361A1 (en) * 2002-08-28 2004-03-19 Pharmacia Corporation Stable ph optimized formulation of a modified antibody
US20040105858A1 (en) * 2002-08-29 2004-06-03 Kim Joanne Young Hee Kwak Diagnosis and treatment of infertility
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
EP2311867A1 (en) 2002-10-29 2011-04-20 Anaphore, Inc. Trimeric binding proteins for trimeric cytokines
US7285269B2 (en) 2002-12-02 2007-10-23 Amgen Fremont, Inc. Antibodies directed to tumor necrosis factor
US7101978B2 (en) 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
WO2004065417A2 (en) * 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
GB0303337D0 (en) * 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
MXPA05008785A (es) * 2003-02-19 2005-10-18 Pharmacia Corp Esteres de polietilen glicol activados.
WO2004098578A2 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising a pde4 inhibitor and a tnf-alfa antagonist selected from infliximab, adalimumab, cdp870 and cdp517
AU2004220325B2 (en) * 2003-06-30 2011-05-12 Domantis Limited Polypeptides
WO2005014649A2 (en) * 2003-08-08 2005-02-17 Pharmacia Corporation Method for the preparation of molecules having antibody activity
JP2007501622A (ja) * 2003-08-13 2007-02-01 サンド・アクチエンゲゼルシヤフト 組換えポリペプチドを精製するための方法
US7785830B2 (en) * 2003-08-13 2010-08-31 Sandoz Ag Expression vectors, transformed host cells and fermentation process for the production of recombinant polypeptides
GB0319601D0 (en) * 2003-08-20 2003-09-24 Sandoz Ag Production process
KR100570422B1 (ko) * 2003-10-16 2006-04-11 한미약품 주식회사 대장균 분비서열을 이용하여 항체 단편을 분비·생산하는 발현벡터 및 이를 이용하여 항체 단편을 대량 생산하는 방법
CN100393748C (zh) * 2003-11-06 2008-06-11 上海中信国健药业有限公司 全人源肿瘤坏死因子抗体，其制备方法以及药物组合物
KR100772800B1 (ko) * 2003-11-17 2007-11-01 주식회사유한양행 인간 종양괴사인자 α를 인식하는 단일클론항체의가변영역 및 이를 코딩하는 유전자
US7435799B2 (en) 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
CN100427504C (zh) * 2004-06-02 2008-10-22 北京天广实生物技术有限公司 TNFα高亲和力嵌合抗体及其用途
JP2008504356A (ja) * 2004-06-30 2008-02-14 ドマンティス リミテッド 炎症性疾患を治療するための組成物及び方法
GB0425972D0 (en) * 2004-11-25 2004-12-29 Celltech R&D Ltd Biological products
WO2006062776A2 (en) * 2004-11-29 2006-06-15 The Regents Of The University Of California Hydroxyapatite-binding peptides for bone growth and inhibition
CN101111521B (zh) * 2004-12-29 2011-08-24 株式会社柳韩洋行 肿瘤坏死因子-α特异性人源化抗体
JP5757495B2 (ja) 2005-05-16 2015-07-29 アッヴィ バイオテクノロジー リミテッド びらん性多発性関節炎の治療のためのｔｎｆ阻害剤の使用
NZ563213A (en) * 2005-06-01 2009-07-31 Micromet Ag Anti-IL2 antibodies
PL2390267T3 (pl) 2005-06-07 2013-09-30 Esbatech A Novartis Co Llc Stabilne i rozpuszczalne przeciwciała hamujące TNF(alfa)
GB0520169D0 (en) * 2005-10-04 2005-11-09 Celltech R&D Ltd Biological products
US9101670B2 (en) 2006-04-07 2015-08-11 Nektar Therapeutics Conjugates of an anti-TNF-α antibody
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
EP2666472A3 (en) * 2006-04-10 2014-04-02 Abbott Biotechnology Ltd Uses and compositions for treatment of psoriatic arthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
JP5385135B2 (ja) 2006-07-03 2014-01-08 チャールズ デイビッド アデア， 細胞接着分子の発現を調節するための組成物
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
WO2008109462A2 (en) * 2007-03-02 2008-09-12 Farnam Companies, Inc. Sustained release pellets comprising wax-like material
EP2166844A4 (en) * 2007-06-07 2013-09-04 Evonik Corp DOSAGE FORMS WITH EXTENDED ACTION AND REDUCED MASS
WO2008154543A2 (en) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis
US8865875B2 (en) 2007-08-22 2014-10-21 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions
CA2712965A1 (en) * 2008-02-05 2009-08-13 Delenex Therapeutics Ag Antigen-binding polypeptides against cartilage degeneration
JP5766598B2 (ja) * 2008-05-07 2015-08-19 アーゴス セラピューティクス インコーポレイテッド ヒトインターフェロン−αに対するヒト化抗体
AU2009264564B2 (en) 2008-06-25 2014-05-08 Novartis Ag Stable and soluble antibodies inhibiting TNFalpha
MX2011000052A (es) 2008-06-25 2011-07-29 Esbatech Alcon Biomed Res Unit Humanizacion de anticuerpos de conejos usando una estructura de anticuerpos universal.
SI2752428T1 (sl) 2008-06-25 2020-03-31 Novartis Ag Humaniziranje zajčjih protiteles z uporabo univerzalnega ogrodja protitelesa
LT3216803T (lt) 2008-06-25 2020-06-10 Novartis Ag Stabilūs ir tirpūs antikūnai, slopinantys vegf
CN101684156B (zh) * 2008-09-27 2011-12-28 苏州工业园区晨健抗体组药物开发有限公司 人TNFα单克隆抗体、其PEG化纳米颗粒及其应用
US20110165063A1 (en) * 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
EP2391652A4 (en) * 2009-01-29 2013-01-02 Abbott Lab IL-1 BINDING PROTEINS
DK2451839T3 (da) 2009-07-10 2020-07-13 Ablynx Nv Fremgangsmåde til produktion af variable domæner
CA2774692C (en) 2009-09-24 2017-12-19 Ucb Pharma S.A. Bacterial strain for recombinant protein expression, having protease deficient degp retaining chaperone activity, and knocked out tsp and ptr genes
MY173390A (en) 2009-10-23 2020-01-22 Takeda Pharmaceuticals Co Anti-gcc antibody molecules and related compositions and methods
GB201000588D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201000587D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000591D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000590D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201001791D0 (en) 2010-02-03 2010-03-24 Ucb Pharma Sa Process for obtaining antibodies
BR112012022342A2 (pt) 2010-03-04 2017-02-14 Vet Therapeutics Inc anticorpos monoclonais dirigidos a cd52
US9616120B2 (en) 2010-03-04 2017-04-11 Vet Therapeutics, Inc. Monoclonal antibodies directed to CD20
JP2013523153A (ja) 2010-04-07 2013-06-17 アッヴィ・インコーポレイテッド ＴＮＦ−α結合タンパク質
GB201012599D0 (en) * 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
GB201012603D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Protein purification
GB201012784D0 (en) * 2010-07-29 2010-09-15 Ucb Pharma Sa Method
TWI538918B (zh) 2010-10-20 2016-06-21 財團法人工業技術研究院 人源化之單株抗體、其核苷酸序列與其用途
AR083495A1 (es) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
CA2837634C (en) 2011-06-01 2021-12-14 Actogenix Nv Polycistronic expression system for bacteria
EP2546267A1 (en) 2011-07-13 2013-01-16 UCB Pharma S.A. Bacterial host strain expressing recombinant DsbC
LT2731973T (lt) 2011-07-13 2018-02-26 Ucb Biopharma Sprl Bakterijų padermė, ekspresuojanti rekombinantinį dsbc
ES2676707T3 (es) 2011-09-23 2018-07-24 Intrexon Actobiotics Nv Bacterias gram positivas modificadas y usos de las mismas
RU2653757C2 (ru) 2011-09-23 2018-05-14 Интрексон Актобиотикс Н.В. Модифицированные грамположительные бактерии и их применение
EP2791169B1 (en) 2011-12-16 2017-07-19 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
GB201208367D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product
US10113002B2 (en) 2012-08-13 2018-10-30 Genentech, Inc. Anti-jagged antibodies and methods of use
JP2017518737A (ja) 2014-04-21 2017-07-13 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ＳＹＫ標的治療薬のための抗ｐＳＹＫ抗体分子及びその使用
WO2016065042A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
ES3046837T3 (en) 2014-12-22 2025-12-02 UCB Biopharma SRL Method of protein manufacture
US11091559B2 (en) 2015-08-27 2021-08-17 Celldex Therapeutics, Inc. Anti-ALK antibodies and methods for use thereof
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
WO2017122180A1 (en) 2016-01-14 2017-07-20 Intrexon Actobiotics N.V. Compositions and methods for the treatment of type 1 diabetes
RU2680011C2 (ru) * 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
AU2017274442B2 (en) * 2016-06-02 2021-08-19 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
PT3658192T (pt) 2017-12-01 2021-06-25 Abbvie Inc Agonista recetor de glucocorticóide e imunoconjugados do mesmo
US12503505B2 (en) 2019-01-31 2025-12-23 Numab Therapeutics AG Multispecific antibodies having specificity for TNFα and IL-17A, antibodies targeting IL-17A, and methods of use thereof
KR102323342B1 (ko) * 2019-04-26 2021-11-08 주식회사 와이바이오로직스 IL-17A 및 TNF-α에 특이적으로 결합하는 이중표적 항체
CN111909268B (zh) * 2019-05-07 2022-04-19 北京天成新脉生物技术有限公司 低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用
TW202237638A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
TW202237639A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 鳥苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
IL305181A (en) 2021-02-15 2023-10-01 Takeda Pharmaceuticals Co Cell therapy compositions and methods for modulating tgf-b signaling
US20250002527A1 (en) 2021-08-26 2025-01-02 Duality Biologics (Suzhou) Co., Ltd. Steroid compound and conjugate thereof
SE545714C2 (en) * 2021-09-24 2023-12-19 Xbrane Biopharma Ab Dna contructs for producing a pelb signal peptide
SE545694C2 (en) * 2021-09-24 2023-12-05 Xbrane Biopharma Ab Dna construct comprising nucleotide sequences encoding amino acid sequences of certolizumab and pelb signal peptides
WO2023046930A1 (en) 2021-09-24 2023-03-30 Xbrane Biopharma Ab Dna constructs and host cells for expressing recombinant protein
WO2023154799A1 (en) 2022-02-14 2023-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination immunotherapy for treating cancer
JP2025534350A (ja) 2022-09-30 2025-10-15 エクステンド バイオサイエンシズ インコーポレーテッド 長時間作用型副甲状腺ホルモン
WO2024180518A1 (en) * 2023-03-01 2024-09-06 Lupin Limited Process for manufacturing antibody fragment protein
TW202525846A (zh) 2023-08-25 2025-07-01 美商普羅特歐拉吉克適美國公司 抗ｉｌ—１３多特異性抗體構築體及其用途
WO2025099576A1 (en) 2023-11-06 2025-05-15 Momenta Pharmaceuticals, Inc. Compositions and methods for treating rheumatoid arthritis

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
US5030570A (en) 1988-06-30 1991-07-09 The Eunice Kennedy Shriver Center For Mental Retardation DNA encoding and method of expressing human monoamine oxidase type A
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
PT92900A (pt) * 1989-01-24 1990-07-31 Sistema de vectores de expressao para a producao de anticorpos monoclonais quimericos
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
DE69420137T2 (de) * 1993-06-03 1999-12-23 Therapeutic Antibodies, Inc. Herstellung von antikörperfragmenten
NO309690B1 (no) 1995-01-23 2001-03-12 Western Atlas Int Inc Detonasjonsanordning av type eksploderende brotråd for bruk med et perforeringsverktöy i en brönn
EP0871641A4 (en) 1995-04-20 2001-09-26 Kennedy Inst Of Rheumatology MULTIPLE ADMINISTRATION OF ANTI-TNF ANTIBODIES
BRPI9707379B8 (pt) 1996-02-09 2015-07-07 Abbvie Biotechnology Ltd Composições farmacêuticas compreendendo anticorpo humano recombinante geneticamente engenheirado, e anticorpo humano recombinante geneticamente engenheirado.
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) * 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
AU9262598A (en) * 1997-08-18 1999-03-08 Innogenetics N.V. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
GB9720054D0 (en) * 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
EP1061954B1 (en) 1998-03-12 2004-06-09 Nektar Therapeutics Al, Corporation Poly(ethylene glycol) derivatives with proximal reactive groups
GB9812545D0 (en) * 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products

Also Published As

Publication number Publication date
CY2010011I1 (el) 2012-01-25
AU6051101A (en) 2001-12-17
BG106278A (bg) 2002-12-29
TWI316088B (en) 2009-10-21
IL147992A0 (en) 2002-09-12
DE122010000027I1 (de) 2010-08-12
EP2230308A1 (en) 2010-09-22
US7012135B2 (en) 2006-03-14
ES2403217T3 (es) 2013-05-16
US20030026805A1 (en) 2003-02-06
EP3059314B1 (en) 2018-10-24
US7977464B2 (en) 2011-07-12
PL353960A1 (en) 2003-12-15
HU230669B1 (hu) 2017-07-28
BR0106682A (pt) 2002-05-14
PE20020292A1 (es) 2002-05-08
MXPA01013440A (es) 2003-09-04
BE2010C019I2 (cg-RX-API-DMAC7.html) 2020-08-20
NO20020554D0 (no) 2002-02-04
ES2230975A1 (es) 2005-05-01
NO339282B1 (no) 2016-11-21
ES2707714T3 (es) 2019-04-04
CZ300737B6 (cs) 2009-07-29
EP3059314A1 (en) 2016-08-24
HK1148776A1 (en) 2011-09-16
RU2303604C2 (ru) 2007-07-27
CY1109889T1 (el) 2012-01-25
FR10C0015I1 (cg-RX-API-DMAC7.html) 2010-04-16
TWI353358B (en) 2011-12-01
PT3059314T (pt) 2019-02-01
IL147992A (en) 2009-06-15
JP2009171966A (ja) 2009-08-06
KR20020047097A (ko) 2002-06-21
ECSP024210A (es) 2002-05-23
NO334808B1 (no) 2014-06-02
DK2230308T3 (da) 2013-05-06
DE60140738D1 (de) 2010-01-21
TR201900227T4 (tr) 2019-02-21
JP2007105043A (ja) 2007-04-26
PL212738B1 (pl) 2012-11-30
PT2308975T (pt) 2016-11-14
CY2019018I2 (el) 2020-05-29
JP2003535591A (ja) 2003-12-02
US20080269465A1 (en) 2008-10-30
EP2308975A1 (en) 2011-04-13
GB0128386D0 (en) 2002-01-16
HUS1700013I1 (hu) 2017-08-28
CA2707766C (en) 2013-05-21
AP2092A (en) 2010-02-28
NO2014026I1 (no) 2014-10-23
PT1287140E (pt) 2010-03-08
CY1118220T1 (el) 2017-06-28
CA2380298C (en) 2010-09-28
CZ2002837A3 (cs) 2002-05-15
IS2808B (is) 2012-09-15
DK2308975T3 (da) 2016-10-31
NL300982I1 (cg-RX-API-DMAC7.html) 2019-05-01
EP1287140A1 (en) 2003-03-05
ZA200200097B (en) 2003-01-06
BG66072B1 (bg) 2011-01-31
SI1287140T1 (sl) 2010-04-30
HUP1600016A2 (en) 2002-10-28
GB0013810D0 (en) 2000-07-26
US7402662B2 (en) 2008-07-22
ES2337763T3 (es) 2010-04-29
BRPI0106682B1 (pt) 2020-10-13
CA2707766A1 (en) 2001-12-13
EP2230308B1 (en) 2013-01-23
GB2366800B (en) 2005-01-19
JP4064812B2 (ja) 2008-03-19
LU91674I9 (cg-RX-API-DMAC7.html) 2019-01-03
NO20131316L (no) 2002-04-08
DK1287140T3 (da) 2010-04-19
EP2308975B1 (en) 2016-08-10
IS3016B (is) 2019-10-15
SI2230308T1 (sl) 2013-06-28
AR033978A1 (es) 2004-01-21
NO20020554L (no) 2002-04-08
NO341218B1 (no) 2017-09-11
PL218516B1 (pl) 2014-12-31
BRPI0106682B8 (pt) 2021-05-25
HUP0202346A3 (en) 2004-11-29
US20020151682A1 (en) 2002-10-17
US20060233800A1 (en) 2006-10-19
JP4476989B2 (ja) 2010-06-09
SK3152002A3 (en) 2002-07-02
HUP0202346A2 (en) 2002-10-28
CY1121173T1 (el) 2020-05-29
ES2600080T3 (es) 2017-02-07
SI2308975T1 (sl) 2016-11-30
PL399351A1 (pl) 2012-12-17
NO20160694A1 (no) 2002-04-08
AU783756B2 (en) 2005-12-01
CA2380298A1 (en) 2001-12-13
CY1114143T1 (el) 2016-07-27
IS6217A (is) 2002-01-03
OA12282A (en) 2006-05-11
WO2001094585A1 (en) 2001-12-13
LT2308975T (lt) 2016-11-10
IL195085A0 (en) 2009-08-03
NO2014026I2 (no) 2018-02-14
FR10C0015I2 (fr) 2011-12-30
TW200817430A (en) 2008-04-16
ES2230975B2 (es) 2007-04-16
US7186820B2 (en) 2007-03-06
NL300982I9 (nl) 2019-05-06
SK288343B6 (sk) 2016-04-01
CN1383450A (zh) 2002-12-04
ATE451460T1 (de) 2009-12-15
CY2010011I2 (el) 2012-01-25
NZ516596A (en) 2004-07-30
DK3059314T3 (en) 2019-02-18
GB2366800A (en) 2002-03-20
PT2230308E (pt) 2013-05-03
MY136603A (en) 2008-10-31
HU230553B1 (hu) 2016-11-28
CY2019018I1 (el) 2020-05-29
EP1287140B1 (en) 2009-12-09
HK1051385A1 (en) 2003-08-01
DE10192353T1 (de) 2003-05-22
AP2002002690A0 (en) 2002-12-31
LU91674I2 (fr) 2010-05-31
HU230561B1 (hu) 2016-12-28
CN1289671C (zh) 2006-12-13
JP5185143B2 (ja) 2013-04-17

Similar Documents

Publication Publication Date Title
BE2017C009I2 (cg-RX-API-DMAC7.html)
BE2013C060I2 (cg-RX-API-DMAC7.html)
BE2012C016I2 (cg-RX-API-DMAC7.html)
BE2009C057I2 (cg-RX-API-DMAC7.html)
FR10C0015I1 (cg-RX-API-DMAC7.html)
BRPI0113085B8 (cg-RX-API-DMAC7.html)
BRPI0110940B8 (cg-RX-API-DMAC7.html)
BE2014C025I2 (cg-RX-API-DMAC7.html)
CH694022C1 (cg-RX-API-DMAC7.html)
BR0112866A2 (cg-RX-API-DMAC7.html)
BRPI0003419A (cg-RX-API-DMAC7.html)
BY5768C1 (cg-RX-API-DMAC7.html)
CN300955183S (zh) 连接件
BRPI0000763B8 (cg-RX-API-DMAC7.html)
CN3133951S (cg-RX-API-DMAC7.html)
CN3138061S (cg-RX-API-DMAC7.html)
AU2000280296A8 (cg-RX-API-DMAC7.html)
AU2000274567A8 (cg-RX-API-DMAC7.html)
BY4905C1 (cg-RX-API-DMAC7.html)
AU2000273097A8 (cg-RX-API-DMAC7.html)
AU2000271150A8 (cg-RX-API-DMAC7.html)
CL2001002979A1 (cg-RX-API-DMAC7.html)
AU2000270757A8 (cg-RX-API-DMAC7.html)
AU2000256911A8 (cg-RX-API-DMAC7.html)
CN3134542S (cg-RX-API-DMAC7.html)